Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology Ltd has applied to the ASX for quotation of 163,122 new ordinary fully paid shares, to be issued on March 26, 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instruments, modestly expanding the company’s share base and potentially enhancing liquidity for investors.
The most recent analyst rating on (AU:RAC) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian-listed biotechnology company focused on oncology. The company is listed on the ASX under the ticker RAC and issues ordinary fully paid shares as its primary traded security in the public equity markets.
Average Trading Volume: 181,275
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$465.4M
See more insights into RAC stock on TipRanks’ Stock Analysis page.